Abstract
With the recently completed sequencing and annotation of the human genome, it has become clear that a significant portion of the genome encodes signal-transducing molecules including receptors, protein kinases, ion channels, transporters and coupling proteins. This review focuses on membrane-localized receptors, which represent the largest single group of signal-transducing molecules. Indeed, one can estimate that nearly 10% of the human genome encodes membrane- localized receptors (e.g. G-protein coupled receptors, ligand-gated ion channels and transporters). We have defined that portion of the human genome that encodes receptors the receptorome. In this article, we will demonstrate how the massively parallel screening of the receptorome provides a facile and under-utilized screening platform for drug discovery. Using case studies, we will show how receptorome-based screening elucidates the mechanisms responsible for serious side-effects of both approved and investigational medications. Additionally, we will provide evidence that receptorome- based screening provides insights into novel therapeutic indications of approved medications and serves to validate targets for therapeutic drug discovery.
Keywords: Obesity-Related Molecular Targets, In Silico Receptoromics, Receptor Databases, GPCR, NC-IUPHAR, Weight Gain
Current Pharmaceutical Design
Title: Screening the Receptorome Yields Validated Molecular Targets for Drug Discovery
Volume: 12 Issue: 14
Author(s): Wesley K. Kroeze and Bryan L. Roth
Affiliation:
Keywords: Obesity-Related Molecular Targets, In Silico Receptoromics, Receptor Databases, GPCR, NC-IUPHAR, Weight Gain
Abstract: With the recently completed sequencing and annotation of the human genome, it has become clear that a significant portion of the genome encodes signal-transducing molecules including receptors, protein kinases, ion channels, transporters and coupling proteins. This review focuses on membrane-localized receptors, which represent the largest single group of signal-transducing molecules. Indeed, one can estimate that nearly 10% of the human genome encodes membrane- localized receptors (e.g. G-protein coupled receptors, ligand-gated ion channels and transporters). We have defined that portion of the human genome that encodes receptors the receptorome. In this article, we will demonstrate how the massively parallel screening of the receptorome provides a facile and under-utilized screening platform for drug discovery. Using case studies, we will show how receptorome-based screening elucidates the mechanisms responsible for serious side-effects of both approved and investigational medications. Additionally, we will provide evidence that receptorome- based screening provides insights into novel therapeutic indications of approved medications and serves to validate targets for therapeutic drug discovery.
Export Options
About this article
Cite this article as:
Kroeze K. Wesley and Roth L. Bryan, Screening the Receptorome Yields Validated Molecular Targets for Drug Discovery, Current Pharmaceutical Design 2006; 12 (14) . https://dx.doi.org/10.2174/138161206776873680
DOI https://dx.doi.org/10.2174/138161206776873680 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gender Disparity in Lipid Target Achievements in High and Very High Atherosclerotic Cardiovascular Disease Risk Patients in the Arabian Gulf
Current Vascular Pharmacology Tracking Stem Cell Therapy in the Myocardium: Applications of Positron Emission Tomography
Current Pharmaceutical Design Effects of Hypoxia and Ischemia on MicroRNAs in the Brain
Current Medicinal Chemistry Meet Our Editorial Board Member
Current Pharmaceutical Biotechnology Strategy for a Genetic Assessment of Antipsychotic and Antidepressant- Related Proarrhythmia
Current Medicinal Chemistry The Long Pentraxin PTX3, a Soluble Pattern Recognition Receptor Involved in Innate Immunity,Inflammation and Female Fertility
Current Immunology Reviews (Discontinued) Myths and Facts Concerning the Use of Statins in Very Old Patients
Cardiovascular & Hematological Disorders-Drug Targets Influence of Physical Immobilization of dsDNA on Carbon Based Matrices of Electrochemical Sensors
Current Pharmaceutical Analysis Effects of Insulin on the Vasculature
Current Vascular Pharmacology Resveratrol and Cancer: Chemoprevention, Apoptosis, and Chemoimmunosensitizing Activities
Current Medicinal Chemistry - Anti-Cancer Agents Hypoxia in Pre-Eclampsia: Cause or Effect?
Current Women`s Health Reviews Trimetazidine Dihydrochloride Pulsatile–Release Tablets for the Treatment of Morning Anginal Symptoms: Dual Optimization, Characterization and Pharmacokinetic Evaluation
Current Drug Delivery Heterocyclic Chalcone Analogues as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Direct and Indirect Measurement of Temporal Horn Volume and Temporal Horn Index and its Neuropsychological Correlation in Mild Cognitive Impaired and Alzheimer Diseased Patients
Current Medical Imaging Patents in the Diagnosis and Therapy of Neurocardiogenic Syncope
Recent Patents on Cardiovascular Drug Discovery Gene Therapy for Cardiovascular Diseases
Current Pharmaceutical Design Propitious Profile of Peppery Piperine
Current Molecular Pharmacology Headache: One of the Most Common and Troublesome Adverse Reactions to Drugs
Current Drug Safety Herbal Medicine as an Alternative Treatment in Autism Spectrum Disorder: A Systematic Review
Current Drug Metabolism Overview of Green Tea Interaction with Cardiovascular Drugs
Current Pharmaceutical Design